The potential for deprescribing in a palliative oncology patient population: a cross-sectional study.

Lisanne N van MerendonkBas J M PetersJulia E MöhlmannCornelis B HuntingElisabeth A KastelijnMarcel P H van den Broek

Published in: European journal of hospital pharmacy : science and practice (2022)

Deprescribing is possible in more than half of palliative oncology patients with a life expectancy of up to 2 years. The adapted deprescribing tool used is non-time consuming and suitable for palliative oncology patients, regardless of age.

Keyphrases

palliative care
advanced cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
physical activity
case report
peritoneal dialysis
patient reported outcomes
human health